Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2021-12-29 00:00:00 ET · period of report 2021-12-29 · accession 0001104659-21-154295 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-29 | 2021-12-29 | TRDA | KREHER NERISSA | Chief Medical Off | M - OptEx | $2.10 | +5,200 | 5,200 | New | +$10.9K |
| D | 2021-12-29 | 2021-12-29 | TRDA | KREHER NERISSA | Chief Medical Off | X - OptEx | $0.00 | -5,200 | 142.7K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-29 | M | A | 5,200 | $2.10 | 5,200 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-12-29 | X | D | 5,200 | $0.00 | 142,722 | D | $2.10 · — to 2030-12-01 | 5,200 Common Stock | (F1) 25% of the shares subject to this option vested and became exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. |